APRIL 23, 2026 AT 11:29 AM
GE HealthCare (GEHC) announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol
Importance
Level 1
#GENERAL ELECTRIC CO#EQUITIES#EU SESSION#US SESSION#INDUSTRIAL CONGLOMERATES#HEALTH CARE EQUIPMENT#INDUSTRIAL CONGLOMERATES (GROUP)#HEALTH CARE EQUIPMENT & SUPPLIES#CAPITAL GOODS#HEALTH CARE EQUIPMENT & SERVICES (GROUP)#S&P 500 INDEX#NASDAQ 100 INDEX#GE#GE HEALTHCARE TECHNOLOGIES INC#GEHC#US EQUITIES